Kronik hemodiyaliz hastalarına uygulanan uzun süreli (9 ay) rekombinant human eritrapoetin (r-HuEPO) tedavisinin hematolojik parametlere etkisi
Date
1992
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Uludağ Üniversitesi
Abstract
Son Dönem Böbrek Yetmezliği (ESRD) olan hastalarda anemi patogenezinde birçok faktör rol oynar. En önemlisi ise eritropoetin yetersizliğidir. Bu nedenle 6 ay ile 5 yıl arasında (Ortalama 3 yıl) haftada üç kez kronik hemodiyaliz programı da olan 8'i erkek (E), 10'u kadın (K) toplam 18 hasta çalışma kapsamına alındı. Hedef Hematokrit (Htc) % 35 kabul edilerek her diyaliz sonunda 50 ü/kg. dozunda i. v. bolus şeklinde r-HuEPO uygulandı. Hematolojik parametreler her iki ayda değerlendirilerek r-HuEPO doz ayarlaması yapıldı. 1 vakada doz 150 ü/kg'a kadar arttırıldı. Tedavi öncesinde ortalama % 20.5 + 5. 7 olan Htc, 2. ayın sonunda ortalama% 25.5 + 5.5'a, 9. ayın sonunda ortalama% 32 + 6'a yükseldi. Aynı şekilde Eritrosit, Retikülosit, Hemoglobin (Hb) ve Trombosit değerlerindeki artışlarda istatistiksel olarak anlamlı bulunurken lökosit sayısında anlamlı fark saptanmadı.
In patients with end stage renal failure, a lot of factory plays important roles in the pathogenesis of anemia. The most important of them is the decrease in Erythropoietin synthesis. Eighteen patients (8 males, 10 females) are selected for the study. They were in a chronic hemodialysis program for a time period between six months and five years. (Mean three years) and they regularly underwent hemodialysis three times a week. Target hematocrit is determined accepted as 35 % and after every hemodialysis. 50 u/kg r-HuEPO is administered by iv route. r-HuEPO dosage adjustment is made by reviewing haematological parameters every two months. In one patient, dosage increased up to 150 u/kg. Hematocrit levels were 20.5 + 5. 7 before treatment, after two months il was mean 25.5 + 5.5 %and of the month mean level was increased to 32 'f 6 %. Similarly, the increases in Erythrocytes, reticulocytes, heamoglobin and platelet levels were statistically significant while differences in leukocyte counts were not significant.
In patients with end stage renal failure, a lot of factory plays important roles in the pathogenesis of anemia. The most important of them is the decrease in Erythropoietin synthesis. Eighteen patients (8 males, 10 females) are selected for the study. They were in a chronic hemodialysis program for a time period between six months and five years. (Mean three years) and they regularly underwent hemodialysis three times a week. Target hematocrit is determined accepted as 35 % and after every hemodialysis. 50 u/kg r-HuEPO is administered by iv route. r-HuEPO dosage adjustment is made by reviewing haematological parameters every two months. In one patient, dosage increased up to 150 u/kg. Hematocrit levels were 20.5 + 5. 7 before treatment, after two months il was mean 25.5 + 5.5 %and of the month mean level was increased to 32 'f 6 %. Similarly, the increases in Erythrocytes, reticulocytes, heamoglobin and platelet levels were statistically significant while differences in leukocyte counts were not significant.
Description
Keywords
Kronik hemodiyaliz, Rekombinant human eritrapoetin, Hematolojik parametler, Hematological parameters, Recombinant human erythropoietin, Chronic hemodialysis
Citation
Yurtkuran, M. vd. (1992). ''Kronik hemodiyaliz hastalarına uygulanan uzun süreli (9 ay) rekombinant human eritrapoetin (r-HuEPO) tedavisinin hematolojik parametlere etkisi''. Uludağ Üniversitesi Tıp Fakültesi Dergisi, 19(2), 219-223.